Scarica l'app Stockscreener
15.63
1.36%
0.21
Dopo l'orario di chiusura:
15.61
-0.02
-0.13%
Precedente Chiudi:
$15.42
Aprire:
$15.77
Volume 24 ore:
2.44M
Relative Volume:
0.80
Capitalizzazione di mercato:
$49.39B
Reddito:
$29.91B
Utile/perdita netta:
$1.30B
Rapporto P/E:
38.54
EPS:
0.4056
Flusso di cassa netto:
$3.49B
1 W Prestazione:
-1.51%
1M Prestazione:
-5.67%
6M Prestazione:
+5.39%
1 anno Prestazione:
+4.90%
Intervallo 1D:
$15.52
$15.77
Intervallo di 1 settimana:
$15.34
$16.02
Portata 52W:
$12.99
$18.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 48.72B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 37.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 32.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 23.41B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | Ripresa | Morgan Stanley | Overweight |
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Takeda Pharmaceutical StockAnalyst sentiment and chart picture on Thursday - AD HOC NEWS
Why Takeda’s Entyvio subcutaneous dose is changing quiet routines for gut patients - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Trades & News - GuruFocus
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda zasocitinib beats deucravacitinib in Phase 3 psoriasis trial - grafa.com
Astellas Pharma Inc. (ALPMY) Stock Price, News, Quote & History - Yahoo Finance
Takeda Pharmaceutical (TAK) Posts Modest Gain: Support Holds, Resistance NearsDescending Triangle - newsline.com
Takeda (TAK) Edges Higher: Approaching Key Resistance Amid Steady Pharma DemandDemand Zone - newsline.com
Dell Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical (ADR) stock (US8740602052): shares fall in New York after shelf registration u - AD HOC NEWS
Takeda (TAK) Stock Slips 1.18% as Shares Approach Key Support AreaShort Setup Alerts - newsline.com
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Pharmaceutical (TAK) Holds Steady at $16.15 Amid Sideways TradingEarnings Miss Risk - newsline.com
Takeda Pharmaceutical (TAK) Faces Resistance at $16.73, Slips 2% Amid Sector WeaknessETF Liquidity - Newser
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Stock Price, Trades & News - GuruFocus
Takeda Pharmaceutical stock (JP3730800003): oncology and rare disease focus after latest earnings up - AD HOC NEWS
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 - Investing.com
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 By Investing.com - Investing.com Canada
Takeda Pharmaceutical stock (JP3730800003): earnings in focus as investors weigh legal risks - AD HOC NEWS
Takeda Pharmaceutical Co Ltd stock (JP3730800003): earnings beat but softer EPS outlook - AD HOC NEWS
Takeda Pharmaceutical stock (JP3730800003): recent earnings and Rybelsus biosimilar plans in focus - AD HOC NEWS
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline - Morningstar
Takeda Pharma ADR earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals - AD HOC NEWS
Takeda Surpasses Earnings Estimates Despite Revenue Miss - HarianBasis.co
What's Going On With Takeda Stock Wednesday?Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga
Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience - Investing.com
Takeda Pharmaceutical stock (JP3730800003): Q4 2026 earnings report released - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd stock (JP3730800003): Is its rare disease focus strong enough to unlock - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock News, Headlines & Updates - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Baskets - GuruFocus
Takeda Pharmaceutical (ADR) stock (US8740602052): Why Google Discover changes matter more now - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Competitors 2026 - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Operating Data - GuruFocus
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.01%
3.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):